RMP
PBYI icon

Richards, Merrill & Peterson’s Puma Biotechnology PBYI Stock Holding History

Richards, Merrill & Peterson’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40
Closed -$122 – 517
2024
Q4 		$122 Buy
+40
New +$116 ﹤0.01% 498

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Richards, Merrill & Peterson's PBYI Position: Q1 2025 in Review

Richards, Merrill & Peterson sold out of Puma Biotechnology (PBYI) in Q1 2025, closing a stake of 40 shares — an estimated $122 sold.

Richards, Merrill & Peterson first reported a position in PBYI in Q4 2024 and held it in 1 quarter. The position peaked at $122 in Q4 2024. 116 funds tracked by Wall St. Rank hold PBYI as of Q1 2025.

  • Richards, Merrill & Peterson reported no remaining Puma Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 40 Puma Biotechnology shares in Q1 2025, an estimated $122.
  • Richards, Merrill & Peterson first reported a position in Puma Biotechnology in Q4 2024 and held it in 1 quarter.
  • Richards, Merrill & Peterson's Puma Biotechnology position peaked at $122 in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q1 2025, filed 7 May 2025.